http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
-
IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain
-
India Globalization Capital, Inc. (IGC) Announces Update On Phase 1 Clinical Trial on Alzheimer's Patients
-
Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients
-
IGC Reports Financial Results for December 31, 2020 Quarter
-
IGC Announces Results of its 2020 Annual Stockholders Meeting
-
IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’s Patients
-
IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
-
IGC Reports Financial Results for the Quarter Ended June 30, 2020 While Preparing for Its FDA-Approved Cannabinoid Clinical Trials on Alzheimer’s Patients
-
CORRECTING and REPLACING IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
-
India Globalization Capital, Inc. (IGC) Announces FDA Approves Initiation of its Cannabinoid Trial on Alzheimer's Patients
-
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients
-
India Globalization Capital, Inc. (IGC) Files Patent Application with the U.S. Patent Office for a New Formulation to Treat Pain
-
IGC Filed a Patent Application with the U.S. Patent Office for a New Formulation to Treat Pain
-
IGC Receives a Notice of Allowance from the U.S. Patent Office
-
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020
-
India Globalization Capital, Inc. Announces Proposed Settlement of Three Derivative Lawsuits and Provides Notice to Shareholders
-
IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals
-
IGC Reports Financial Results for the Quarter Ended December 31, 2019
-
IGC Reports Financial Results for the Quarter Ended September 30, 2019
-
IGC Opens Marketing and Research Hub in Colombia
-
India Globalization Capital, Inc. (IGC) Reports IRB Approval of IGC-AD1 for Phase-2 Study
-
IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 study
-
IGC Reports Financial Results for the Quarter Ended June 30, 2019
-
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2019
-
IGC to Participate in Arizona’s Industrial Hemp Program
-
IGC Announces Continued Educational Initiatives in Support of Hyalolex
-
IGC (IGC) says its cannabinoid-based, non-FDA approved product to assist in improve lives of patients with Alzheimer's disease will be available for purchase in San Juan
-
IGC Provides Corporate Updates
-
IGC Announces Successful Appeal of Delisting Proceedings and Imminent Relisting on NYSE American
-
IGC to Re-list Securities on Alternative Exchange
-
NYSE American to Suspend Trading in India Globalization Capital and Commence Delisting Proceedings
-
India Globalization Capital, Inc. (IGC) Files Provisional Patent to Protect IP for CBD-Infused Energy Drink
-
IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink
-
India Globalization Capital, Inc. (IGC) Prices 5.65M Share At-the-Market Offering at Approx. $5.30/Sh
-
IGC Completes At-The-Market Offerings
-
India Globalization Capital (IGC) to Enter Hemp/CBD-Infused Energy Drink Space
-
IGC to Enter the Hemp/CBD-Infused Energy Drink Space
-
India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolex Commercialization
-
IGC to Enter California Market with Hyalolex
-
IGC Announces Results of its 2018 Annual Stockholders Meeting
-
IGC Announces Financial Results for Quarter Ended June 30, 2018
-
IGC Announces “Drops of Clarity” Marketing Initiatives for Hyalolex™
-
IGC Annual Meeting of Stockholders: August 6, 2018
-
India Globalization Capital Files Patent for Hyalolex Formulation
-
Puerto Rican Alzheimer’s Patients to Be First in U.S. to Obtain Cannabis-Based Relief
-
IGC Partners to Advance Cannabinoid Based Parkinson's Disease Therapy Research -- CFN Media
-
India Globalization Capital Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD
-
India Globalization Capital Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorde
-
IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage

